

Editorial

Natural Products for Chronic Diseases: A Ray of Hope

Syed Shams ul Hassan ^{1,2,*} , Mohamed M. Abdel-Daim ^{3,4} , Tapan Behl ⁵ and Simona Bungau ^{6,7} 

¹ Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China

² Department of Natural Product Chemistry, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China

³ Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah 21442, Saudi Arabia

⁴ Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt

⁵ School of Health Sciences and Technology, University of Petroleum and Energy Studies, Dehradun 248007, Uttarakhand, India

⁶ Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania

⁷ Doctoral School of Biomedical Sciences, University of Oradea, 410087 Oradea, Romania

* Correspondence: shams1327@yahoo.com

This Special Issue includes many high advanced quality papers that focus on natural products with their potent pharmacological potential targeting various areas of diseases. The papers in this Special Issue present new insights into natural products with potent anticancer, anti-inflammatory, antioxidant, anti-bacterial, analgesic, anti-diabetic, and enzyme inhibitory activities.

Secondary metabolites from nature, predominantly plants, are still a research hotspot because of their promising novel scaffolds against chronic diseases. Plant-derived bioactive compounds were proved to have promising anticancer activities. Recently, many researchers have driven their research interest toward plants to evaluate the use of plant-derived bioactive compounds against different kinds of cancer. Hassan and his team [1] evaluated one guaiane-type sesquiterpene dimer vieloplain F from *Xylopi* Vielana species against melanoma by targeting B-Raf kinase. The results indicated that vieloplain F has good anticancer activity against melanoma by displaying a higher binding energy of -11.8 kcal/mol against B-Raf protein compared to the FDA-approved drug vemurafenib. Further MD simulations and MM-GBSA showed that vieloplain F had the most remarkable binding propensity to active site residues. In addition, the absorption, distribution, metabolism, excretion, and toxicity (ADMET) profile of the FDA-approved medicine vemurafenib was hepatotoxic, cytochrome-inhibiting, and non-cardiotoxic compared to vieloplain F, which at this moment has been selected for further investigation due to its potential effects against melanoma. Majid et al. [2] isolated a new triterpenoid nummularic acid (NA) from *Ipomoea batatas* and evaluated its anticancer activity against prostate cancer (PCa). The results showed that significant ($p < 0.05$ and $p < 0.01$) time and dose-dependent reductions in the proliferation of PCa cells, reduced migration, invasion, and an increased apoptotic cell population were recorded after NA treatment (3–50 μ M). Further profound mechanistic studies revealed that NA treatment considerably increased the cleavage of caspases and downstream PARP, upregulated BAX and P53, and downregulated BCL-2 and NF- κ B, inducing apoptosis in PCa cells. Khan et al. [3] evaluated the effects of DL-propargylglycine (PAG, inhibitor of CSE), aminoxy acetic acid (AOAA, inhibitor of CBS), and L-aspartic acid (L-Asp, inhibitor of 3-MPST) against breast cancer (BC) by determining the role of endogenous H₂S in the growth of BC by performing in vitro and in vivo experiments. The results showed that the combined dose (PAG + AOAA + L-Asp) group showed exclusive inhibitory effects against BC cells' viability, proliferation, migration, and invasion compared to the control group. Further, treated cells exhibited increased apoptosis and a



Citation: Hassan, S.S.u.; Abdel-Daim, M.M.; Behl, T.; Bungau, S. Natural Products for Chronic Diseases: A Ray of Hope. *Molecules* **2022**, *27*, 5573. <https://doi.org/10.3390/molecules27175573>

Received: 23 August 2022

Accepted: 25 August 2022

Published: 30 August 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

reduced level of phospho (p)-extracellular signal-regulated protein kinases such as p-AKT, p-PI3K, and p-mTOR. Moreover, the combined group exhibited potent inhibitory effects on the growth of BC xenograft tumors in nude mice without apparent toxicity.

Natural products have a broad pharmacological spectrum because of their complex scaffolds. Huneif et al. [4] isolated two compounds from wild strawberries and evaluated their anti-diabetic and antioxidant activity. The results showed that both compounds have good anti-diabetic activity against α -glucosidase, α -amylase, and antioxidant activity against DPPH free radicals. Al-Joufi et al. [5] evaluated the anti-diabetic, antioxidant, and anti-microbial potential of the *Anabasis articulata* plant. The results showed that different extracts (methanolic and n-hexane) displayed remarkable anti-diabetic activity against α -glucosidase, α -amylase, antioxidant activity against DPPH free radicals and anti-microbial activity against *Shigella dysentery* (*S. dynasties*), *Escherichia coli* (*E. coli*), and *Salmonella typhi* (*S. typhi*). Ahmed et al. [6] evaluated the vegetable plant *Pleurospermum candollei* by investigating its phytochemical profile and biological activities such as antioxidant, anti-bacterial, thrombolytic and enzyme inhibitory characteristics (tyrosinase, α -amylase, and α -glucosidase). The results displayed that methanolic and n-hexane extracts showed remarkable pharmacological activities in terms of antioxidant, anti-bacterial, thrombolytic and enzyme inhibitory characteristics. In addition, pure compounds also displayed good docking results against targeted proteins. Mahmood et al. [7] evaluated the anti-inflammatory, analgesic and antioxidant capacity of New (2S,3S)-2-(4-isopropylbenzyl)-2-methyl-4-nitro-3-phenylbutanals. The results revealed that two compounds have potent anti-inflammatory activity in vitro against COX $\frac{1}{2}$ and 5-LOX, antioxidant activity against DPPH free radicals and in vivo analgesic activity. Faheem et al. [8] investigated the effects of natural compounds, berbamine, bergapten, and carveol on paclitaxel-associated neuroinflammatory pain. The results revealed that all the compounds attenuated thermal hypersensitivity and increased the threshold for pain sensation. The compounds also increased the protective glutathione (GSH) and glutathione S-transferase (GST) levels in the sciatic nerve and spinal cord while lowering inducible nitric oxide synthase (iNOS) and lipid peroxidase (LPO). Furthermore, the compounds also inhibited cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF- α), and nuclear factor kappa B (NF- κ b) overexpression.

Glensk et al. [9] isolated bioactive compounds echimidine and its C-7 isomers from *Echium plantagineum* L. and evaluated their hepatotoxic effect on rat hepatocytes. The results revealed that the compounds at 3 to 300 μ g/mL caused the concentration-dependent inhibition of hepatocyte viability, with mean IC₅₀ values ranging from 9.26 to 14.14 μ g/mL. This study revealed that under standard HPLC acidic conditions, echimidine co-elutes with its isomers, echihumiline and to a lesser degree with hydroxy myoscorpine, obscuring the actual alkaloidal composition, which may have implications for human toxicity. Khan et al. [10] evaluated the effects of shrimp peptide hydrolysate on intestinal microbiota restoration and immune modulation in cyclophosphamide-treated mice. The results showed that shrimp peptide hydrolysate significantly restored goblet cells and intestinal mucosa integrity, modulated the immune system, and increased the relative expression of mRNA and the tight-junction associated proteins occludin, Zo-1, claudin-1, and mucin-2).

Marine drugs possess an undoubtedly diverse range of sources as they are distributed over 70% of the earth's surface, possess a wide range of variations in structure and present a promising target in the discovery of newer and better treatment approaches. In the past seven decades, many structurally diverse drug products and their secondary metabolites have been isolated from marine sources which have successfully presented an exceptional potential in the treatment of various diseases ranging from acute to chronic conditions. Hence, Bhatia et al. [11] highlighted the significant role of marine-derived drugs in the management of chronic diseases such as diabetes, cancer, cardiovascular and neurodegenerative disorders.

Principally, the Special Issue "Natural Products for Chronic Diseases: A Ray of Hope" provides a current perspective of the natural products from the marine and terrestrial area and the rapidly developing research area, as evident from the resistance to the available drugs and wide variety of chronic diseases. Considering the challenges in this exciting

field of natural products drug discovery, this issue not only complements our knowledge on bioactive compounds but also may uncover some novel ideas and motivation for the further investigation of various prospective biologically active compounds impacting medical practice.

Funding: This research received no external funding.

Acknowledgments: We express our sincere thanks to the contributing authors, the reviewers who reviewed the submitted manuscripts and contributed to the quality of the manuscripts, and the editorial staff of *Molecules* for their support throughout the process.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Shams ul Hassan, S.; Qamar Abbas, S.; Ali, F.; Ishaq, M.; Bano, I.; Hassan, M.; Jin, H.-Z.; Bungau, S.G. A Comprehensive In Silico Exploration of Pharmacological Properties, Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from *Xylopia vielana* Targeting B-Raf Kinase. *Molecules* **2022**, *27*, 917. [[CrossRef](#)] [[PubMed](#)]
2. Majid, M.; Farhan, A.; Asad, M.I.; Khan, M.R.; Hassan, S.S.U.; Haq, I.-U.; Bungau, S. An Extensive Pharmacological Evaluation of New Anti-Cancer Triterpenoid (Nummularic Acid) from *Ipomoea batatas* through In Vitro, In Silico, and In Vivo Studies. *Molecules* **2022**, *27*, 2474. [[CrossRef](#)]
3. Khan, N.H.; Wang, D.; Wang, W.; Shahid, M.; Khattak, S.; Ngowi, E.E.; Sarfraz, M.; Ji, X.-Y.; Zhang, C.-Y.; Wu, D.-D. Pharmacological Inhibition of Endogenous Hydrogen Sulfide Attenuates Breast Cancer Progression. *Molecules* **2022**, *27*, 4049. [[CrossRef](#)]
4. Huneif, M.A.; Alqahtani, S.M.; Abdulwahab, A.; Almedhesh, S.A.; Mahnashi, M.H.; Riaz, M.; Ur-Rahman, N.; Jan, M.S.; Ullah, F.; Aasim, M.; et al. α -Glucosidase, α -Amylase and Antioxidant Evaluations of Isolated Bioactives from Wild Strawberry. *Molecules* **2022**, *27*, 3444. [[CrossRef](#)] [[PubMed](#)]
5. Al-Joufi, F.A.; Jan, M.; Zahoor, M.; Nazir, N.; Naz, S.; Talha, M.; Sadiq, A.; Nawaz, A.; Khan, F.A. *Anabasis articulata* (Forssk.) Moq: A Good Source of Phytochemicals with Antibacterial, Antioxidant, and Antidiabetic Potential. *Molecules* **2022**, *27*, 3526. [[CrossRef](#)] [[PubMed](#)]
6. Ahmed, M.; Khan, K.-R.; Ahmad, S.; Aati, H.Y.; Ovatlarnporn, C.; Rehman, M.S.; Javed, T.; Khursheed, A.; Ghalloo, B.A.; Dilshad, R.; et al. Comprehensive Phytochemical Profiling, Biological Activities, and Molecular Docking Studies of *Pleurospermum candollei*: An Insight into Potential for Natural Products Development. *Molecules* **2022**, *27*, 4113. [[CrossRef](#)]
7. Mahmood, F.; Khan, J.A.; Mahnashi, M.H.; Jan, M.S.; Javed, M.A.; Rashid, U.; Sadiq, A.; Hassan, S.S.U.; Bungau, S. Anti-Inflammatory, Analgesic and Antioxidant Potential of New (2S,3S)-2-(4-isopropylbenzyl)-2-methyl-4-nitro-3-phenylbutanals and Their Corresponding Carboxylic Acids through In Vitro, In Silico and In Vivo Studies. *Molecules* **2022**, *27*, 4068. [[CrossRef](#)] [[PubMed](#)]
8. Faheem, M.; Khan, A.; Saleem, M.W.; Shah, F.A.; Ali, F.; Khan, A.W.; Li, S. Neuroprotective Effect of Natural Compounds in Paclitaxel-Induced Chronic Inflammatory Pain. *Molecules* **2022**, *27*, 4926. [[CrossRef](#)] [[PubMed](#)]
9. Gleńsk, M.; Dudek, M.K.; Kinkade, P.; Santos, E.C.S.; Glinski, V.B.; Ferreira, D.; Seweryn, E.; Kaźmierski, S.; Calixto, J.B.; Glinski, J.A. Isolation of Echimidine and Its C-7 Isomers from *Echium plantagineum* L. and Their Hepatotoxic Effect on Rat Hepatocytes. *Molecules* **2022**, *27*, 2869. [[CrossRef](#)] [[PubMed](#)]
10. Khan, A.I.; Rehman, A.U.; Farooqui, N.A.; Siddiqui, N.Z.; Ayub, Q.; Ramzan, M.N.; Wang, L.; Xin, Y. Effects of Shrimp Peptide Hydrolysate on Intestinal Microbiota Restoration and Immune Modulation in Cyclophosphamide-Treated Mice. *Molecules* **2022**, *27*, 1720. [[CrossRef](#)] [[PubMed](#)]
11. Bhatia, S.; Makkar, R.; Behl, T.; Sehgal, A.; Singh, S.; Rachamalla, M.; Mani, V.; Iqbal, M.S.; Bungau, S.G. Biotechnological Innovations from Ocean: Transpiring Role of Marine Drugs in Management of Chronic Disorders. *Molecules* **2022**, *27*, 1539. [[CrossRef](#)] [[PubMed](#)]